Skip to main content
Top
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

Authors: M Nelson, G Amaya, N Clumeck, C Arns Da Cunha, D Jayaweera, P Junod, L Taisheng, P Tebas, M Stevens, A Buelens, S Vanveggel, K Boven

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

TMC278 had a high virologic response rate, non-inferior to EFV, in two Phase III double-blind trials ECHO (TMC278-C209, NCT00540449) and THRIVE (TMC278-C215, NCT00543725) in treatment-naïve HIV-infected adult patients. As the use of NNRTIs, particularly nevirapine, has been associated with hepatic-related adverse events (AEs), especially in HIV/hepatitis B (HBV) and/or hepatitis C (HCV) co-infected patients, a subgroup analysis of these events was performed on the pooled Week 48 Phase III data. …
Metadata
Title
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
Authors
M Nelson
G Amaya
N Clumeck
C Arns Da Cunha
D Jayaweera
P Junod
L Taisheng
P Tebas
M Stevens
A Buelens
S Vanveggel
K Boven
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P210

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue